[1] 丁勇, 马庆杰, 王任飞,等. 分化型甲状腺癌术后131I治疗前评估专家共识[J]. 中国癌症杂志, 2019, 29(10):832-840. DING Yong, MA Qingjie, WANG Renfei, et al. Expert consensus on pre-evaluation of 131I treatment for differentiated thyroid carcinoma after operation[J]. China Oncology, 2019, 29(10): 832-840. [2] 中华医学会核医学分会.131I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(4):218-241. Chinese Society of Nuclear Medicine.Guidelines for radioiodine therapy of differentiated thyroid cancer (2021 Edition)[J]. Chin J Nucl Med Mol Imaging, 2021, 41(4):218-241. [3] 文静, 殷成宇, 廖国伟,等. 应用GM(1,1)灰色模型预测全国甲状腺癌发病趋势[J]. 现代肿瘤医学, 2022, 30(5):899-902. WEN Jing, YIN Chengyu, LIAO Guowei. Application of GM(1,1)model in predicting the incidence trend of thyroid cancer in China[J]. J Mod Oncol, 2022, 30(5):899-902. [4] 中华人民共和国国家卫生健康委员会医政医管局. 甲状腺癌诊疗指南(2022年版)[J]. 中国实用外科杂志, 2022, 42(12): 1343-1357+1363. National Health Commission of the People's Republic of China Medical Administration and Hospital Adminitration.Guidelines for the diagnosis and treatment of thyroid carcinoma[J]. Chin J Pract Surg, 2022, 42(12): 1343-1357+1363. [5] 邢海群, 巴建涛, 王瞳, 等. 核医学治疗病房放射性131-I污染的监测与评价[J]. 中国医学科学院学报, 2015, 37(6):730-732. XING Haiqun, BA Jiantao, WANG Tong, et al. Nuclear medicine treatment area: Monitoring and evaluation of radioactive 131-I contamination[J]. Acta Acad Med Sin, 2015, 37(6): 730-732. [6] Jo K, Lim D J. Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer[J]. Korean J Intern Med, 2018,33(6):1050-1057. [7] Mattar E, Salih M A, Alsafi K, et al. Radiation protection in the release of patients receiving 131I treatment[J]. Radiation Protection Dosimetry, 2019, 187(4):499-508. [8] 王鑫淼, 王军平, 冉新泽. 我国临床核医学发展现状及相关人员放射防护措施探究[J]. 辐射防护, 2020, 40(4):331-339. WANG Xinmiao, WANG Junping, RAN Xinze. Current situation of clinical nuclear medicine in China and exploration of radiological protection for relevant staff[J]. Radiat Prot, 2020, 40(4): 331-339. [9] Al-Mohammed H I, Sulieman A, Mayhoub F H, et al. Occupational exposure and radiobiological risk from thyroid radioiodine therapy in Saudi Arabia[J]. Scientific Reports, 2021, 11(1): 1-8. [10] 中国疾病预防控制中心辐射防护与核安全医学所, 中国医学科学院放射医学研究所, 广东省职业病防治院, 等. 核医学放射防护要求: GBZ 120—2020[S]. 北京:中国标准出版社, 2020. [11] 张海霞, 赵敏, 牟小娟, 等. 核素污染被服防护车的设计和应用[J]. 医疗卫生装备, 2015, 36(12):151-152. ZHANG Haixia, ZHAO Min, MOU Xiaojuan, et al. Design and application of protective vehicle for radionuclide contaminated quilt clothing[J]. Chinese Medical Equipment Journal, 2015, 36(12):151-152. [12] Yonekura Y, Mattsson S, Flux G, et al. ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals. Ann ICRP. 2019,48(1):5-95. [13] 郑隽. 甲状腺癌术后患者131I治疗期间辐射防护的管理[J]. 护士进修杂志, 2012, 27(8):685-686. ZHENG Juan. Management of radiation protection in postoperative patients with thyroid cancer during 131I therapy[J]. Journal of nurses training, 2012, 27(8):685-686. [14] 施冰梓, 杨素云, 辛笛诺. 131I治疗分化型甲状腺癌患者被服辐射残余剂量率影响因素分析及防护建议[J]. 护理学报, 2022, 29(7):69-73. SHI Bingzi, YANG Suyun, XIN Dinuo. Analysis of influencing factors of radiation residual dose rate in patients with differentiated thyroid cancer treated with 131I and protective suggestions[J]. Journal of Nursing, 2022, 29(7):69-73. [15] 中华人民共和国生态环境部. 核医学辐射防护与安全要求: HJ 1188—2021[S]. 北京:中国环境出版社,2021. [16] 胡凤琼, 庞华, 杨俊卿, 等. 甲状腺癌患者大剂量131I治疗的辐射防护研究[J]. 重庆医学, 2014, 43(17):2252-2253. HU Fengqiong, PANG Hua, YANG Junqin, et al. Study on radiation protection of patients with thyroid cancer treated with high-dose 131I[J]. Chongqing Medicine, 2014, 43(17):2252-2253. [17] 黄立群, 李曙芳, 孙鸽, 等. 放射性核素的治疗应用及展望[J]. 同位素,2021,34(4):412-420. HUANG Liqun, LI Shufang, SUN Ge, et al. Current applications and prospects of radionuclide for therapy[J]. Journal of Isotopes, 2021, 34(4):412-420. [18] International Commission on Radiological Protection. Radiological protection in therapy with radiopharmaceuticals[R]. ICRP Publication 140.Oxford: Pergamon Press, 2019. [19] International Atomic Energy Agency. Radiation protection and safety of radiation sources: International Basic Safety Standards: IAEA Safety Standards Series No. GSR Part 3[R]. Vienna: IAEA, 2014. [20] International Atomic Energy Agency. Application of the concepts of exclusion, exemption and clearance: IAEA Safety Standards Series No. RS-G-1.7[R]. Vienna: IAEA, 2004. [21] Ravichandran R, Binukumar J P, Sreeram R, et al. An overview of radioactive waste disposal procedures of a nuclear medicine department[J]. J Med Phys, 2011, 36(2): 95-99. DOI: 10.4103/0971-6203.79692. [22] Al-Haj A N, Lobriguito A M, Al Anazi I. Radioactive waste handling and disposal at King Faisal Specialist Hospital and Research Centre[J]. Health Phys, 2012, 103(Suppl 2): 144-150. DOI: 10.1097/HP.0b013e318254543e. [23] Environment Agency. Radioactive substances regulation (RSR): objective and principles[EB/OL]. (2021-12-01)[2024-04-12]. https://www.gov.uk/government/publications/radioactive-substances-regulation-rsr-objective-and-principles/radioactive-substances-regulation-rsr-objective-and-principles#the-rsr-objective. [24] 中华医学会核医学分会, 中国核学会核医学分会. 核医学科建设与管理指导意见(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(12):748-754. Chinese Society of Nuclear Medicine, Nuclear Medicine Branch of Chinese Nuclear Society.Guiding opinions on the construction and management of the department of nuclear medicine(2021 Edition)[J]. Chin J Nucl Med Mol Imaging, 2021, 41(12):748-754. [25] 中华人民共和国住房和城乡建设部, 国家发展和改革委员会. 综合医院建设标准: JB 110—2008[S].重庆: 重庆出版社,2008. [26] 中华人民共和国国家卫生健康委员会. 综合医院建设标准: 110—2021[S]. 北京: 中国计划出版社,2021. |